Experimental Cancer Vaccine Shows Promise in Animal Studies
Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced on Thursday, Nov. 10, that an experimental, therapeutic cancer vaccine showed promise in an animal (mice) study, and induced two distinct and desirable immune system responses that led to significant tumor regression in mice. The researchers found that intravenous (IV) administration of the vaccine boosted the number of (cytotoxic) T cells capable of infiltrating and attacking tumor cells, and engaged the innate immune system by inducing type I interferon. The innate immune response modified the tumor microenvironment, counteracting suppressive forces
